肝移植在非标准肝脏恶性肿瘤中的应用突破与挑战

摘要/Abstract

摘要： 随着肝脏供体库的扩大(如技术改进、活体移植、丙型肝炎治愈)及传统适应证患者逐渐减少,肝移植(LT)的应用探索正扩展至“非标准”肝脏恶性肿瘤患者,包括肝内/肝门部胆管癌、神经内分泌肿瘤肝转移和结直肠癌肝转移等。最新研究证据表明,经过严格筛选(基于肿瘤负荷、生物学行为、治疗反应等),此类患者接受LT后,5年无复发生存率可达到50%,提示LT对特定非标准肿瘤具有潜在治愈价值。尽管仍面临肿瘤异质性、复发风险和获益评估等挑战,但值得深入探索及研究。

关键词: 肝移植, 非标准肿瘤, 肝细胞癌, 移植获益, 生存分析

王新帅, 李善宝, 徐军明. 肝移植在非标准肝脏恶性肿瘤中的应用突破与挑战[J]. 肝脏, 2025, 30(9): 1180-1182.

/ 推荐

参考文献

[1] Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699.
[2] Chairi M H M, González M M, Alonso A J P, et al. Liver transplantation in patients with hepatocellular carcinoma: long-term survival results[J]. Transplant Proc, 2022, 54(1): 48-50.
[3] Rodríguez-Perálvarez M, Gómez-Bravo MÁ, Sánchez-Antolín G, et al. Expanding indications of liver transplantation in Spain: consensus statement and recommendations by the Spanish society of liver transplantation[J]. Transplantation, 2021, 105(3): 602-607.
[4] Lucey M R, Furuya K N, Foley D P. Liver transplantation[J]. N Engl J Med, 2023, 389(20): 1888-1900.
[5] Zilbert N Sapisochin G. Time to reconsider liver transplantation for intrahepatic cholangiocarcinoma?[J]. Lancet Gastroenterol Hepatol, 2018, 3(5): 294-295.
[6] Sapisochin G, de Lope C R, Gastaca M, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study[J]. Ann Surg, 2014, 259(5): 944-952.
[7] Takahashi K, Obeid J, Burmeister C S, et al. Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis[J]. Ann Transplant, 2016, 21: 208-215.
[8] Kodali S, Kulik L, D'Allessio A, et al. The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma[J]. Liver Transpl, 2025, 31(6): 815-831.
[9] Achurra P, Fernandes E, O'Kane G, et al. Liver transplantation for intrahepatic cholangiocarcinoma: who, when and how[J]. Curr Opin Organ Transplant, 2024, 29(2): 161-171.
[10] Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for “very early” intrahepatic cholangio-carcinoma: International retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4): 1178-1188.
[11] Lunsford K E, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018, 3(5): 337-348.
[12] McMillan R R, Javle M, Kodali S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma[J]. Am J Transplant, 2022, 22(3): 823-832.
[13] Meyer C G, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients[J]. Transplantation, 2000, 69(8): 1633-1637.
[14] De Vreede I, Steers J L, Burch P A, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma[J]. Liver Transpl, 2000, 6(3): 309-316.
[15] Heimbach J K, Haddock M G, Alberts S R, et al. Transplantation for hilar cholangiocarcinoma[J]. Liver Transpl, 2004, 10(10 Suppl 2): S65-8.
[16] Rea D J, Heimbach J K, Rosen C B, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma[J]. Ann Surg, 2005, 242(3): 451-461.
[17] 李智宇.结直肠癌肝转移外科治疗相关问题思考[J]. 肝癌电子杂志, 2019, 6(02): 15-18.
[18] Hagness M, Foss A, Line P D, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer[J]. Ann Surg, 2013, 257(5): 800-806.
[19] Dueland S, Grut H, Syversveen T, et al. Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis[J]. Am J Transplant, 2020, 20(2): 530-537.
[20] Adam R, Piedvache C, Chiche L, et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial[J]. Lancet, 2024, 404(10458): 1107-1118.
[21] Hernandez-Alejandro R, Ruffolo L I, Sasaki K, et al. Recipient and donor outcomes after living-donor liver transplant for unresectable colorectal liver metastases[J]. JAMA Surg, 2022, 157(6): 524-530.
[22] Line P D, Hagness M, Berstad A E, et al. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept[J]. Ann Surg, 2015, 262(1): e5-e9.
[23] White B E, Rous B, Chandrakumaran K, et al. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study[J]. Lancet Reg Health Eur, 2022, 23: 100510.
[24] Mazzaferro V, Pulvirenti A,Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?[J]. J Hepatol, 2007, 47(4): 460-466.
[25] Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors[J]. Am J Transplant, 2016, 16(10): 2892-2902.
[26] Le Treut Y P, Grégoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study[J]. Ann Surg, 2013, 257(5): 807-815.
[27] Ciria R, Ivanics T, Aliseda D, et al. Liver transplantation for primary and secondary liver tumors: patient-level meta-analyses compared to UNOS conventional indications[J]. Hepatology, 2025, 81(6): 1700-1713.
[28] Moeckli B, Majno P, Orci L A, et al. Liver transplantation selection and allocation criteria for hepatocellular carcinoma: a European perspective[J]. Semin Liver Dis, 2021, 41(2): 172-181.